Brought to you by 
Medgenics completes its IPO on the NYSE
14 Nov 2011
Executive Summary
Medgenics Inc. (combination therapeutics/devices for sustained treatment of chronic diseases) has netted $10.9mm through its initial public offering on the New York Stock Exchange. After filing in November 2010, the company announced plans two months ago to sell 2.5mm shares for between $4-7 each. It finalized the offering by selling 2.62mm shares (including the overallotment) at $4.54, with five-year warrants to purchase another 2.8mm shares at $6 apiece.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medgenics completes its IPO on the NYSE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice